13therapeutics

Executive Summary

13therapeutics is a private biopharmaceutical company headquartered in San Diego, CA, focused on discovering and developing novel anti-inflammatory peptide therapeutics for high-unmet medical needs. Founded in 2021, the company leverages proprietary platforms to identify and optimize peptide candidates targeting inflammatory pathways, aiming to address conditions such as autoimmune disorders and chronic inflammation where current treatments are suboptimal. By focusing on peptide-based modalities, 13therapeutics seeks to combine high specificity with favorable safety profiles, positioning itself in the competitive anti-inflammatory space. Despite being in early stages of development, 13therapeutics has established a promising pipeline of preclinical candidates. The company's progress will depend on advancing lead programs toward clinical trials, securing additional funding, and forming strategic partnerships. As a private entity, limited public information is available, but the company's focus on validated targets and peptide therapeutics offers a differentiated approach. Key risks include early-stage uncertainty and competition from larger players. Overall, 13therapeutics represents a high-risk, high-reward opportunity contingent on successful execution of its development plans.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Peptide Candidate40% success
• Q4 2026Series A or B Financing Round Announcement60% success
• Q1 2027Preclinical Data Presentation at Major Conference50% success